← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pharmain Corporation
Seattle, WA
$23,835,826
Total funding
18
Grants
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,835,826 · 18
By mechanism
R44$18,214,383 · 7
R43$5,621,443 · 11
Investigators at Pharmain Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Subcutaneous Drug Development for Portal Hypertension Ascites$2,638,464
R44 · FY2025 · DK
Subcutaneous Drug Development for Portal Hypertension Ascites$2,145,275
R44 · FY2024 · DK
CMC of Peptide Formulation for the Treatment of ARDS$999,993
R44 · FY2022 · HL
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP$999,661
R44 · FY2017 · HL
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP$999,596
R44 · FY2018 · HL
Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human$995,100
R44 · FY2023 · CA
Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human$995,099
R44 · FY2024 · CA
Subcutaneous Drug Development for Portal Hypertension Ascites$992,469
R44 · FY2021 · DK
Subcutaneous Drug Development for Portal Hypertension Ascites$982,292
R44 · FY2022 · DK
CMC of Peptide Formulation for the Treatment of ARDS$967,740
R44 · FY2023 · HL
Long Acting Native GLP-1 formulations for Type 1 Diabetes$960,879
R44 · FY2008 · DK
Long Acting Native GLP-1 formulations for Type 1 Diabetes$959,053
R44 · FY2009 · DK
Long Acting Native GLP-1 formulations for Type 1 Diabetes$914,882
R44 · FY2007 · DK
EGF/Gastrin for Islet Regeneration$794,040
R44 · FY2013 · DK
EGF/Gastrin for Islet Regeneration$749,606
R44 · FY2014 · DK
Targeted formulations of GLP -1 for Type 1 diabetes$500,945
R43 · FY2004 · DK
Targeted formulations of GLP -1 for Type 1 diabetes$499,654
R43 · FY2005 · DK
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR$432,304
R44 · FY2011 · AA
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR$350,624
R44 · FY2010 · AA
Long-acting VIP formulations for the treatment of chronic inflammatory diseases$300,000
R43 · FY2010 · AI